- Home
- HGTY vs WVE Comparison
HGTY vs WVE Comparison
Compare HGTY & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HGTY
- WVE
- Stock Information
- Founded
- HGTY 1984
- WVE 2012
- Country
- HGTY United States
- WVE Singapore
- Employees
- HGTY N/A
- WVE N/A
- Industry
- HGTY Specialty Insurers
- WVE Biotechnology: Pharmaceutical Preparations
- Sector
- HGTY Finance
- WVE Health Care
- Exchange
- HGTY Nasdaq
- WVE Nasdaq
- Market Cap
- HGTY 934.4M
- WVE 915.6M
- IPO Year
- HGTY N/A
- WVE 2015
- Fundamental
- Price
- HGTY $11.21
- WVE $9.76
- Analyst Decision
- HGTY Hold
- WVE Strong Buy
- Analyst Count
- HGTY 3
- WVE 16
- Target Price
- HGTY $10.50
- WVE $20.00
- AVG Volume (30 Days)
- HGTY 267.4K
- WVE 1.6M
- Earning Date
- HGTY 08-04-2025
- WVE 07-30-2025
- Dividend Yield
- HGTY N/A
- WVE N/A
- EPS Growth
- HGTY 90.09
- WVE N/A
- EPS
- HGTY 0.20
- WVE N/A
- Revenue
- HGTY $1,303,397,000.00
- WVE $93,946,000.00
- Revenue This Year
- HGTY $15.41
- WVE N/A
- Revenue Next Year
- HGTY $15.88
- WVE $4.55
- P/E Ratio
- HGTY $54.28
- WVE N/A
- Revenue Growth
- HGTY 17.90
- WVE N/A
- 52 Week Low
- HGTY $8.03
- WVE $5.04
- 52 Week High
- HGTY $12.35
- WVE $16.74
- Technical
- Relative Strength Index (RSI)
- HGTY 58.29
- WVE 72.03
- Support Level
- HGTY $8.81
- WVE $8.40
- Resistance Level
- HGTY $11.44
- WVE $9.03
- Average True Range (ATR)
- HGTY 0.50
- WVE 0.55
- MACD
- HGTY 0.07
- WVE 0.06
- Stochastic Oscillator
- HGTY 91.06
- WVE 98.53
About HGTY Hagerty Inc.
Hagerty Inc is a provider of specialty automotive insurance. The company underwrites, sells, and services classic car and enthusiast vehicle insurance policies. Substantial revenue is derived from Commission and fees. Geographically it serves Europe, Canada, and the United States.
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.